Low-level of mitochondrial DNA alterations during direct-acting antiviral treatment in leukocytes of people who inject drugs living with HCV
5 affiliations
- 1Pathogenesis and Control of Chronic and Emerging Infections, Montpellier University, INSERM, University of Antilles, CHU Montpellier, Montpellier, France
- 2Department of Biochemistry and Molecular Biology, University Hospital of Angers, Angers, France
- 3University of Angers, MITOVASC Research Unit, CNRS 6015, INSERM U1083, Angers, France
- 4HaiPhong Medical University, Haiphong, Vietnam
- 5Supporting Community Development Initiatives, Hanoi, Vietnam
Abstract
Direct-acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment, offering high cure rates and favorable safety profiles. However, concerns remain regarding their long-term mitochondrial safety, particularly among vulnerable populations such as people who inject drugs (PWID), who are frequently exposed to multiple mitotoxic agents. This longitudinal study investigated mitochondrial DNA (mtDNA) instability, including deletions and single-nucleotide variants, among PWID living with HCV during DAA treatment, using whole mitochondrial genome sequencing. We analyzed samples of 33 PWID living with HCV before treatment (baseline), at the end of treatment (week 12), and after long-term follow-up (week 48), in comparison with 30 HCV-seronegative PWID. Associations with clinical events were assessed during a 3-year follow-up after study completion. mtDNA deletions were detected in 9.1% of PWID living with HCV at baseline and increased to 19.2% post-treatment, whereas no mtDNA deletions were observed in HCV-seronegative PWID. Heteroplasmy levels (i.e., proportion of mutated to wild-type mtDNA) remained below 1%. Variants were widespread in both HCV-positive and HCV-seronegative PWID, predominantly in the non-coding D-loop region. A small number of low-heteroplasmy treatment-emergent variants were detected during follow-up, but none persisted at long-term follow-up. No significant associations were found between mtDNA instability and hepatic or splenic complications assessed at 3 years. These findings suggest that DAA exposure is associated with low-level mtDNA instability in blood leukocytes. Nonetheless, long-term mitochondrial surveillance is warranted, especially in post-mitotic tissues, to fully assess the implications of cumulative mitotoxic exposures in this high-risk population.
IMPORTANCE: Direct-acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment, but their safety is still under debate. Given the nature of these regimens, mitochondrial genotoxicity could represent a potential off-target effect. We searched for mitochondrial DNA alterations in people who inject drugs living with HCV. The prevalence of HCV infection is high in this population, and any potential toxicity would be exacerbated as they are exposed to other mitotoxic drugs. We detected low-level mitochondrial DNA alterations in blood leukocytes, including a modest increase in mitochondrial DNA deletions, but these alterations remained at very low levels (below 1%) and were not associated with any clinical complications during 3 years of follow-up. These findings provide reassuring evidence regarding the short-term mitochondrial safety of DAA treatment in blood leukocytes while supporting the need for longer-term studies in post-mitotic tissues.
CLINICAL TRIALS: This study is registered with Clinical Trial Registry as NCT03526939 and NCT03537196.
Related
- Hepatic Mitochondrial Alterations in GLP-1 Poor Responders Undergoing Roux-en-Y Gastric Bypass
- Adenovirus infection and disease in paediatric haematopoietic stem cell transplant patients: clues for antiviral pre-emptive treatment
- High Frequency of Circulating IL-4R+SELL+ Naïve B Cells Is Associated with Functional Cure in Chronic Hepatitis B Patients Receiving Antiviral Treatment
- Advances in the treatment of brain metastases in non-small cell lung cancer with rare driver-gene alterations
- NAD+ precursor treatment prevents cardiomyopathy but disrupts erythroid maturation in mitochondrial progeria
BibTeX
@article{gay2026lowlevel,
title = {{Low-level of mitochondrial DNA alterations during direct-acting antiviral treatment in leukocytes of people who inject drugs living with HCV}},
author = {Laetitia Gay and Clara Rapenne and Valérie Desquiret-Dumas and Roselyne Vallo and Quynh Bach Thi Nhu and Linh Le Thi Thuy and Huong Thi Duong and Binh Nguyen Thanh and Catherine Quillet and Hong Thi Tran and Thanh Nham Thi Tuyet and Oanh Khuat Thi Hai and Vinh Vu Hai and Khue Pham Minh and Nicolas Nagot and Didier Laureillard and Pascal Reynier and Jean-Pierre Molès},
journal = {Microbiology Spectrum},
year = {2026},
month = oct,
doi = {10.1128/spectrum.01946-26},
url = {https://doi.org/10.1128/spectrum.01946-26},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Low-level of mitochondrial DNA alterations during direct-acting antiviral treatment in leukocytes of people who inject drugs living with HCV
AU - Laetitia Gay
AU - Clara Rapenne
AU - Valérie Desquiret-Dumas
AU - Roselyne Vallo
AU - Quynh Bach Thi Nhu
AU - Linh Le Thi Thuy
AU - Huong Thi Duong
AU - Binh Nguyen Thanh
AU - Catherine Quillet
AU - Hong Thi Tran
AU - Thanh Nham Thi Tuyet
AU - Oanh Khuat Thi Hai
AU - Vinh Vu Hai
AU - Khue Pham Minh
AU - Nicolas Nagot
AU - Didier Laureillard
AU - Pascal Reynier
AU - Jean-Pierre Molès
PY - 2026
DA - 2026/10/09
JO - Microbiology Spectrum
DO - 10.1128/spectrum.01946-26
UR - https://doi.org/10.1128/spectrum.01946-26
AB - Direct-acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment, offering high cure rates and favorable safety profiles. However, concerns remain regarding their long-term mitochondrial safety, particularly among vulnerable populations such as people who inject drugs (PWID), who are frequently exposed to multiple mitotoxic agents. This longitudinal study investigated mitochondrial DNA (mtDNA) instability, including deletions and single-nucleotide variants, among PWID living with HCV during DAA treatment, using whole mitochondrial genome sequencing. We analyzed samples of 33 PWID living with HCV before treatment (baseline), at the end of treatment (week 12), and after long-term follow-up (week 48), in comparison with 30 HCV-seronegative PWID. Associations with clinical events were assessed during a 3-year follow-up after study completion. mtDNA deletions were detected in 9.1% of PWID living with HCV at baseline and increased to 19.2% post-treatment, whereas no mtDNA deletions were observed in HCV-seronegative PWID. Heteroplasmy levels (i.e., proportion of mutated to wild-type mtDNA) remained below 1%. Variants were widespread in both HCV-positive and HCV-seronegative PWID, predominantly in the non-coding D-loop region. A small number of low-heteroplasmy treatment-emergent variants were detected during follow-up, but none persisted at long-term follow-up. No significant associations were found between mtDNA instability and hepatic or splenic complications assessed at 3 years. These findings suggest that DAA exposure is associated with low-level mtDNA instability in blood leukocytes. Nonetheless, long-term mitochondrial surveillance is warranted, especially in post-mitotic tissues, to fully assess the implications of cumulative mitotoxic exposures in this high-risk population. IMPORTANCE: Direct-acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment, but their safety is still under debate. Given the nature of these regimens, mitochondrial genotoxicity could represent a potential off-target effect. We searched for mitochondrial DNA alterations in people who inject drugs living with HCV. The prevalence of HCV infection is high in this population, and any potential toxicity would be exacerbated as they are exposed to other mitotoxic drugs. We detected low-level mitochondrial DNA alterations in blood leukocytes, including a modest increase in mitochondrial DNA deletions, but these alterations remained at very low levels (below 1%) and were not associated with any clinical complications during 3 years of follow-up. These findings provide reassuring evidence regarding the short-term mitochondrial safety of DAA treatment in blood leukocytes while supporting the need for longer-term studies in post-mitotic tissues. CLINICAL TRIALS: This study is registered with Clinical Trial Registry as NCT03526939 and NCT03537196.
SN - 2165-0497
ER -